A rising number of patients is expected to benefit from the use of neuromodulation devices in the next 5 years according to LSI's new analysis, "Global Markets for Neuromodulation Devices and Implantable Infusion Pumps in 2016." The report discusses the major forces affecting growth in the markets for implantable infusion pumps; neuromodulation devices used for established applications such as chronic pain, sensorineural hearing loss, gastroparesis, urinary incontinence, fecal incontinence, epilepsy, major depression, Parkinson's disease, essential tremor, and dystonia; and neuromodulation systems intended for novel uses such as congestive heart failure, obstructive sleep apnea, and vision loss. Expanded indications and the adoption of neuromodulation devices for previously untapped patient populations are expected to drive growth throughout the global market, which was valued at $4.6 billion in 2015. This in-depth analysis provides detailed segmentation for neuromodulation devices and implantable infusion pumps in the U.S., Europe, and the rest of the world.
Benefits of this report:
© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
